Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01395004 · ClinicalTrials.gov registry record · Phase 2
A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis
A Phase 2 study of Langerhans Cell Histiocytosis, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
- 5
- Study locations
NCT01395004 is a Phase 2 study of Langerhans Cell Histiocytosis that has completed, run by GlaxoSmithKline. The registered enrollment target is 17 participants, below the 1,137-participant average among 8 other Langerhans Cell Histiocytosis trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT01395004, a Phase 2 study of Langerhans Cell Histiocytosis, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study was to assess safety and efficacy at months 3 and 6 in patients with Langerhans Cell Histiocytosis given daily oral doses of GSK2110183.
Conditions Studied
Interventions
- DRUG GSK2110183
Study Locations (5)
New York
- Memorial Sloan Kettering Cancer Center - New York
- Staten Island University Hospital - Staten Island
Maryland
- Johns Hopkins Hospital - Baltimore
Massachusetts
- Dana Farber Cancer Institute - Boston
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2011-11 |
| Est. Completion | 2013-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01395004
The ClinicalTrials.gov registry entry for NCT01395004 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,137-participant average among 8 other Langerhans Cell Histiocytosis trials with a reported enrollment target (99% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Langerhans Cell Histiocytosis appearing as the primary indexed condition, and to 1 intervention - of which GSK2110183 is the first listed.
NCT01395004 reports 5 study locations spanning 4 distinct geographic areas - top geographies include New York, Maryland, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01395004 about?
NCT01395004 is a clinical study titled "A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis". The purpose of this study was to assess safety and efficacy at months 3 and 6 in patients with Langerhans Cell Histiocytosis given daily oral doses of GSK2110183.
What is the current status of trial NCT01395004?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2011-11. Estimated completion is 2013-11.
What conditions does trial NCT01395004 study?
This clinical trial studies the following conditions: Langerhans Cell Histiocytosis.
What interventions are being tested in trial NCT01395004?
The interventions under investigation include: GSK2110183 (DRUG).
Who is sponsoring clinical trial NCT01395004?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01395004 being conducted?
This trial has 5 study locations across Maryland, Massachusetts, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Langerhans Cell Histiocytosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib
RECRUITING · Phase 2
-
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
RECRUITING · Phase 2
-
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
RECRUITING · Phase 2
-
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
ACTIVE NOT RECRUITING · Phase 2
-
Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders
ACTIVE NOT RECRUITING · Phase 2
-
Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With LCH
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.